Dennis P. Scanlon, PhD, professor, Health Policy and Administration, and director, Center for Health Care and Policy Research, Pennsylvania State University, discusses how well the United States health system scales successful pilots in delivering value-based care across the country.
Dennis P. Scanlon, PhD, professor, Health Policy and Administration, and director, Center for Health Care and Policy Research, Pennsylvania State University, discusses how well the United States health system scales successful pilots in delivering value-based care across the country.
Transcript
When there are successful pilots in delivering value-based care, how well does the United States health system scale these pilots across country?
There have been many pilots in terms of attempting to sort of incorporate value into cared delivery, which of course I would define as better aligning the way care is provided with the payment system. To answer the question, I don’t think we’ve really gotten to scale yet. I think these have remained pilots. I think, probably, the scale that’s happened has happened within organizations and scaling across organizations, so taking programs that they’ve done and branching them out into multiple ambulatory clinics or other acute care hospitals or integrating across their system. I think less so, broadly speaking, across the market or across the country.
You know, that’s not to say that there aren’t some examples. But, I think one of the big barriers frankly, and as was talked about in this meeting is, that we’re still largely in a discounted fee for service-based payment arrangement, so there really isn’t the incentive to scale these things as much as maybe some people had hoped. I think a lot of the organizations that are doing work in this, the delivery systems that are doing work, are ones that are making a bet, forward thinking, that this is the way the payment landscape is really going to go and that its worth going down this path. In fact, I’ve talked to some who have said, “we know what we’re doing is losing money or at least not covering the investment that were making, but we believe that it’s worth kind of getting experience with these programs now, these pilots now, because it will pay off in the future.”
So again, to go back to the question, I don’t think we’ve had nearly the level of scale that was envisioned by CMS, by many others, as we talked about expectations for value-based payment models. It’s sort of that thing that everybody seems to be involved in, but it hasn’t grown quite at the rate that we expected it to be.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More